Stockscreener 앱 받기
3.67
96.26%
1.80
시간 외 거래:
3.19
-0.48
-13.08%
전일 마감가:
$1.87
열려 있는:
$4.23
하루 거래량:
91.63M
Relative Volume:
62.54
시가총액:
$2.64M
수익:
-
순이익/손실:
$-11.28M
주가수익비율:
-1.2193
EPS:
-3.01
순현금흐름:
$-9.78M
1주 성능:
+95.21%
1개월 성능:
+6.38%
6개월 성능:
-39.02%
1년 성능:
-56.18%
1일 변동 폭
$3.26
$4.85
1주일 범위
$1.62
$4.85
52주 변동 폭
$1.62
$14.67
Ensysce Biosciences Inc Stock (ENSC) Company Profile
명칭
Ensysce Biosciences Inc
전화
(858) 263-4196
주소
7946 IVANHOE AVENUE, LA JOLLA
ENSC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
3.67 | 2.64M | 0 | -11.28M | -9.78M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.42 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.85 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.65 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.97 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.13 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Ensysce Biosciences Inc 주식(ENSC)의 최신 뉴스
Ensysce Biosciences to raise $2.2 million through warrant exercise By Investing.com - Investing.com Canada
Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga
Ensysce Biosciences announces exercise of warrants for $2.2M gross proceeds - MSN
Ensysce Biosciences to raise $2.2 million through warrant exercise - Investing.com Australia
Ensysce Biosciences Inc’s Shares Reel: -58.79% Quarterly Revenue Decline Amid 5.62M Market Cap - investchronicle.com
Ensysce Biosciences Stock Doubles In One Trading SessionHere's Why - Yahoo
Dropbox Inc: Weathering Stock Market Storms with 7.92B Market Cap - investchronicle.com
Nuvation Bio Inc Inc. (NUVB) Price Performance: A Technical Analysis Perspective - investchronicle.com
Ensysce Biosciences Raises Fresh $2.2M Capital: H.C. Wainwright Backs Strategic Warrant Deal - Stock Titan
Analysts Are Recommending Ensysce Biosciences Inc (ENSC) As A Buy Candidate - Marketing Sentinel
Ensysce Biosciences Inc (NASDAQ:ENSC) stock: You might be surprised - uspostnews.com
Amentum Holdings Inc (AMTM) Shares Are Down -4.43% YTD - Marketing Sentinel
Crude Oil Falls Over 3%; Philip Morris Earnings Top Views - Benzinga
The Psychology of Altria Group Inc Inc. (MO) Price Performance: Understanding Market Sentiment - investchronicle.com
(ENSC) Technical Data - news.stocktradersdaily.com
Safety Shot Inc Inc. (SHOT) Price Performance: A Technical Analysis Perspective - investchronicle.com
Dow Jumps Over 1,000 Points; Tesla Shares Rise After Q1 Results - Benzinga
Trump's Trade Hints Spark US Equity Gains - Finimize
Ensysce Biosciences secures patent for OUD treatment By Investing.com - Investing.com India
Ensysce Biosciences Gets US Patent for Opioid Use Disorder Treatment; Shares Rise Pre-Bell - marketscreener.com
AtlasClear Holdings Inc (ATCH) Stock: A Year of Stock Market Dynamics - investchronicle.com
Revolutionary Opioid Treatment Patent Promises Safer Alternative to Methadone: Key Advantages Revealed - Stock Titan
An In-Depth Look At TPG Inc (TPG) - Marketing Sentinel
DVS’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Ensysce Biosciences files to sell 652,439 shares of common stock for holders - MSN
ENSC stock touches 52-week low at $1.7 amid market challenges By Investing.com - Investing.com South Africa
ENSC stock touches 52-week low at $1.7 amid market challenges - Investing.com UK
Comparing Ensysce Biosciences (NASDAQ:ENSC) & MacroGenics (NASDAQ:MGNX) - Defense World
Pre-market Movers: CHRO, QURE, FOTA, LLY... - RTTNews
Ensysce Biosciences (ENSC) Plans to Sell Over 650,000 Shares - GuruFocus
Ensysce Biosciences completes key trial phase for safer opioid - Investing.com
Ensysce Biosciences announces data from opioid overdose protection study - TipRanks
Ensysce Biosciences completes key trial phase for safer opioid By Investing.com - Investing.com India
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Revolutionary Opioid Drug Shows Breakthrough Overdose Protection in Clinical Trial - Stock Titan
Ensysce Biosciences Stock Rises On Positive Data From Opioid Overdose Protection Study: Retail’s Thrilled - MSN
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
ENSC stock touches 52-week low at $2.11 amid market challenges - Investing.com
After-Hour Gains For Ensysce Biosciences (ENSC) Signal Renewed Interest - Stocks Telegraph
Ensysce Biosciences Secures $1.1 Million in Registered Direct Offering, Prices 315,188 Shares at $3.49 per Share - AInvest
Ensysce Biosciences corrects SEC filing omission By Investing.com - Investing.com South Africa
Ensysce Biosciences corrects SEC filing omission - Investing.com
Ensysce Biosciences raises $1.1 million in stock sale By Investing.com - Investing.com South Africa
Ensysce Biosciences prices 315,188 shares at $3.49 in registered direct offering - TipRanks
Ensysce Biosciences raises $1.1 million in stock sale - Investing.com
Ensysce Raises Fresh Capital: Strategic $1.1M Investment Powers Next-Gen Pain Drug Pipeline - Stock Titan
Ensysce Biosciences Reminds Shareholders to Vote At Upcoming 2022 Virtual Annual Shareholder Meeting - ACCESS Newswire
(ENSC) On The My Stocks Page - news.stocktradersdaily.com
Ensysce Biosciences Advances in Opioid Innovation - TipRanks
Revolutionary Opioid Safety Technology Takes Center Stage at PAINWeek 2025 - StockTitan
How the (ENSC) price action is used to our Advantage - news.stocktradersdaily.com
Ensysce Biosciences Inc (ENSC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.69%
21.50%
자본화:
|
볼륨(24시간):